Canaccord initiates Deere as buy

JOE, I BEGIN WITH YOU. DEERE INITIATED, PRICE TARGET 30% HIGHER THAN WHERE IT IS NOW. LET'S START THERE. YOU OWN THAT PERSONAL AND IN THE JOET >> I'VE OWNED DEERE LONGER THAN IT'S BEEN IN THE JOET, SINCE 2021 ON SEVERAL DIFFERENT THEORIES NUMBER ONE BEING THAT WE WOULD SEE AGRICULTURE HAVE THIS SIGNIFICANT POSITIVE CYCLE, AND THEN IN ADDITION TO THAT THE REPLACEMENT CYCLE FOR FARM EQUIPMENT

AND WE'RE SEEING THE REALITY OF THAT. SO DEERE HAS BEEN A STRONG PERFORMER. REVENUE GROWTH IS ACCELERATING IN THE LAST YEAR VERSUS 11% THE LAST THREE YEARS IS THE MOMENTUM GETTING STRETCHED? YES. AND A LOT OF THAT, THE RESOLUTION WILL COME WHERE AGRICULTURE PRICES ARE ON THE DECLINE. >> WEISS, YOU DIDN'T OWN IT THAT LONG BUT DID YOU SELL IT TOO EARLY? >> NO. LOOK, YOU'RE

SEEING INVENTORIES BUILD AT THE DEALERSHIPS THE COST OF BUYING A NEW TRACTOR, JUST LOOK WHERE RATES ARE. WHAT IT COSTS TO LEASE OR BUY A CAR, FINANCING YOU'RE SEEING AGRICULTURAL PRICES COME DOWN THEY'RE GETTING SQUEEZED ON WHAT THEY HAVE TO PAY FOR A NEW TRACTOR. I THINK LONG TERM IT'S A GREAT STORY. IT'LL GET THERE AGAIN. >> CORTEVA, $75 IS THE PRICE TARGET YOU OWN THAT

IN THE T. >> THAT'S A STRETCH. IT WAS ADDED IN OCTOBER OF LAST YEAR YOU ASK YOURSELF WHEN YOU HAVE TWO COMPANIES THAT YOU OWN IN SIMILAR INDUSTRIES YOU COMPARE THE TWO. I'M LESS EXCITED ABOUT CORTEVA TRADES AT 27 TIMES THE REVENUE GROWTH IS 6% IT'S AGRICULTURE SPECIFIC. THE BIOTAKE STORY WILL TAKE HOLD AND BE A CATALYST THAT'S REALLY A STRETCH. >> REGENERON DOWNGRADED. YOU OWN

THIS >> I OWN IT AND THE STOCK DOWN 10% ON DELAY I THINK THIS IS A FANTASTIC FRANCHISE AND A REALLY GOOD OPPORTUNITY TO GET IN. DUPIXENT HAS A DOUBLE DIGIT NUMBER IN THEIR TRIALS IT'S A GREAT SCIENCE COMPANY >> JOET IN THE T >> WE HAVE A DECENT PROFIT ON IT THIS IS A QUALITY COMPANY THAT TRADES AT 17 TIMES IN THE FDA'S SUBMITTAL, THIS

REALLY IS MORE OF A MANUFACTURING ISSUE. >> IT'S A THIRD PARTY FILLER ISSUE. >> IT'S NOT SAFETY OR EFFICACY IT'S CORRECTIBLE IT'S ABOUT MANAGING TIME WHICH REGENERON IS A LEADER IN EYE THERAPY DRUGS. >> NIKE GETS A CALL, TOO, CUT TO 146 FROM 152 AT JPMORGAN THE TOP-RANKED RETAIL ANALYST. AMY, LONG-TERM HOLDING WHAT DO WE THINK ABOUT THIS? >> THEY'RE GOING TO REPORT TOMORROW NIGHT A

LOT OF BAD NEWS IN THE SPACE, FOOT LOCKER, ET CETERA IT'S CHEAP RELATIVE TO ITS OWN HISTORY. GOING DIRECT WILL HELP THEIR MARGINS AND THAT'S THEIR OBJECTIVE. >> JOE, YOU OWN IT, TOO. >> A TERRIBLE PURCHASE END OF APRIL. STRAIGHT DOWN EVER SINCE INVENTORY ISSUES PERSIST FOR THIS COMPANY WE'VE HAD MULTIPLE PRICE DOWNGRADES THEY WILL HAVE TO IMPROVE TO SEE THE STOCK REGAIN SOME POSITIVE MOMENTUM

>> DO YOU HAVE A DIFFERENT TAKE? >> THERE HAS BEEN A LOT OF NEGATIVE NEWS IN THE SECTOR. MORE PEOPLE ARE SHORT THAN LONG WHICH COULD GET A SHORT SQUEEZE AS A RESULT. WHAT THEY'RE DOING, THEIR PARTNERSHIP WITH ATHLETES, I THINK THIS IS THE NAME TO OWN IN SPACE. >> DOES IT DESERVE THE MULTIPLE IT HAS NOW >> I THINK TRADING 28 TIMES -- >> FORWARD

31. >> IT COULD COME DOWN. EARNINGS HAVE BEEN DEPRESSED THEY HAVE BEEN MISSING SO I DON'T EXPECT ANYTHING NEAR TERM BUT LONGER TERM THEY'RE POSITIONED TO TAKE OUT THEIR MIDDLEMAN. >> I THINK PART OF THE ISSUE IS FOOT LOCKER, BY THE WAY. NIKE AND THE SELECTION IS JUST NOT THERE. THEY'VE GIVEN IT TO DICK